Maha Katabi

Maha joined Sofinnova as a Partner in 2019. In 2020, she was promoted to General Partner. She is an experienced investor in biopharma companies, with over two decades in venture capital investing and public equities portfolio management. She focuses on development stage investments in therapeutics. Maha represents Sofinnova as a member of the board of directors for Amplyx Pharmaceuticals, Northsea Therapeutics and Aerovate Therapeutics.

Prior to joining Sofinnova, Maha was a Managing Partner of Oxalis Capital. Prior to founding Oxalis in 2018, Maha was a Partner at Sectoral Asset Management since 2008, where she formed and led a dedicated investment team and advisory board to drive investments in private companies. Two of these companies were Ascendis and Apellis, both also Sofinnova portfolio companies. Additionally, she was a Portfolio Manager for a family of funds, that invested in publicly listed and private healthcare companies. Prior to Sectoral, Maha was Vice-President at Ventures West Management since 2004, a venture capital firm focusing on technology and life sciences in Canada and the United States. She started her venture capital career in 1999 at T2C2 Capital Bio, a seed fund focused on Canadian start-ups.

Maha received her PhD in Pharmacology and BSc in Biology from McGill University, and is a CFA charterholder. She is currently Chair of the board of Exactis Innovation, a Canadian oncology precision medicine network.